Erenumab Disease Interactions

Constipation is a common side effect of erenumab therapy and while it is usually mild or moderate in intensity, there have been postmarketing reports of constipation with serious complications including hospitalization and surgery. Onset of constipation was generally after the first dose, although there were reports later in treatment. Patients should be monitored for severe constipation and managed as clinically appropriate. Patients with history of constipation or using medications associated with decreased gastrointestinal motility may be at increased risk for more severe constipation.

Hypertension and worsening of preexisting hypertension have been reported in the postmarketing period with erenumab; some patients required pharmacologic treatment and some required hospitalization to control blood pressure. Many patients had preexisting hypertension or risk factors for hypertension. Monitor patients for new onset or worsening hypertension and consider discontinuing therapy if no other cause for hypertension is identified.